Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
about
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyMonoclonal antibodies: versatile platforms for cancer immunotherapy.Fc receptor inside-out signaling and possible impact on antibody therapy.Rituximab resistance.Consensus statement on the use of rituximab in patients with rheumatoid arthritisTargeted therapy for hematologic malignancies.Neutrophils in antibody-based immunotherapy of cancer.Follicular lymphoma: the case for timely intervention.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Combination strategies to enhance antitumor ADCC.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.FcγR requirements leading to successful immunotherapy.Neutrophils in cancer.Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas.Immunotherapy for B-cell lymphoma: current status and prospective advances
P2860
Q27691388-01350DC6-607D-40B2-8AA2-512626C169AFQ28270899-CD4CB55B-B900-43A2-A3ED-6DD8C205550AQ34111693-96E0886E-D050-4E9A-9E8F-FAFF9A353A0DQ34499280-5A7F52E1-BE36-474D-A6D3-85773C8F1D3EQ35041270-04F76E7B-A668-499F-97BA-1D301F5B00D8Q35638676-770E5395-928A-4CAA-BDBB-BCE818CFEDC9Q36108610-445C7F7F-F93D-47DE-9217-73218C493BD9Q37032641-E5F2BDE5-F9C8-4AF6-8124-1F0854D74E35Q37810093-2104FDD9-36B0-4806-9EA0-B4227CC67475Q37832694-53F1F399-FB43-44F7-9507-9106299C136BQ38014085-5B627C95-602C-4770-A7DE-93BDE37B21DBQ38273851-116B36B3-DDBD-4059-AE7B-ADB13246870FQ38355000-091EAA5D-34CF-4733-9449-DA2051339AF2Q38615360-D2138E41-C6B0-48D5-ADF7-5F06A52511CCQ38936555-D723E2AD-C949-48F0-9316-11E974A3AD3FQ40355709-AD09AD4D-6325-4983-B4D7-D18395A37B34Q41061029-85EC1DFE-11D7-4233-8A36-8A5C4F9B59DAQ41831989-12BC9D37-10F5-49DA-B73C-3FE91B9AE12F
P2860
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Treatment of relapsed B-cell n ...... report on safety and efficacy.
@en
type
label
Treatment of relapsed B-cell n ...... report on safety and efficacy.
@en
prefLabel
Treatment of relapsed B-cell n ...... report on safety and efficacy.
@en
P2093
P2860
P356
P1433
P1476
Treatment of relapsed B-cell n ...... report on safety and efficacy.
@en
P2093
Grillo-López AJ
van Oers MH
van der Kolk LE
P2860
P2888
P304
P356
10.1038/SJ.LEU.2402995
P577
2003-08-01T00:00:00Z
P5875
P6179
1017653237